H-IALILEPICCQERAA-OH

Ref. 3D-PP43039

Informations sur le produit

• Nom: H-IALILEPICCQERAA-OH
• Synonymes: NH2-Ile-Ala-Leu-Ile-Leu-Glu-Pro-Ile-Cys-Cys-Gln-Glu-Arg-Ala-Ala-OH

Description

Peptide H-IALILEPICCQERAA-OH is a Research Peptide with significant interest within the field academic and medical research. This peptide is available for purchase at Cymit Quimica in multiple sizes and with a specification of your choice. Recent citations using H-IALILEPICCQERAA-OH include the following: Peptide Inhibitor of Complement C1 (PIC1) Inhibits Growth of Pathogenic Bacteria PS Hair, M Gregory Rivera, AI Enos - Journal of Peptide , 2019 - Springerhttps://link.springer.com/article/10.1007/s10989-017-9651-z Peptide inhibitor of complement C1 inhibits the peroxidase activity of hemoglobin and myoglobin PS Hair, KM Cunnion - Journal of Peptides, 2017 - Wiley Online Libraryhttps://onlinelibrary.wiley.com/doi/abs/10.1155/2017/9454583 Inhibition of complement activation, myeloperoxidase, NET formation and oxidant activity by PIC1 peptide variants PS Hair, AI Enos, NK Krishna , KM Cunnion - PLoS One, 2019 - journals.plos.orghttps://journals.plos.org/plosone/article?id=10.1371/journal.pone.0226875 The EPICC Family of Anti-Inflammatory Peptides: Next Generation Peptides, Additional Mechanisms of Action, and In Vivo and Ex Vivo Efficacy NK Krishna , KM Cunnion , GA Parker - Frontiers in Immunology, 2022 - frontiersin.orghttps://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2022.752315/full Peptide inhibitor of complement C1 (PIC1) rapidly inhibits complement activation after intravascular injection in rats JA Sharp , PS Hair, HK Pallera , PS Kumar - PLoS , 2015 - journals.plos.orghttps://journals.plos.org/plosone/article?id=10.1371/journal.pone.0132446 A patent review of myeloperoxidase inhibitors for treating chronic inflammatory syndromes (focus on cardiovascular diseases, 2013-2019) J Soubhye, P Van Antwerpen - Expert opinion on , 2020 - Taylor & Francishttps://www.tandfonline.com/doi/abs/10.1080/13543776.2020.1780210 Patent highlights June-July 2019 HAM Mucke - Pharmaceutical Patent Analyst, 2019 - Future Sciencehttps://www.future-science.com/doi/full/10.4155/ppa-2019-0019 ESTUDIO ALEATORIZADO, DOBLE CIEGO, CONTROLADO CON PLACEBO, DE DOS PARTES (DOSIS acašNICA ASCENDENTE Y DOSIS MacašLTIPLES ECAII SI, LIZNTYI SI - interoperabilidad.incmnsz.mxhttp://interoperabilidad.incmnsz.mx:8080/Inv2014/seguimiento_protocolo/protocolos/RLS_0071-102_Solicitud%20de%20evaluacion%20del%20comite%20etica%202019_Dr.%20Chiquete%20(1).docx A complement-mediated rat xenotransfusion model of platelet refractoriness AI Enos, PS Hair, NK Krishna , KM Cunnion - Molecular Immunology, 2020 - Elsevierhttps://www.sciencedirect.com/science/article/pii/S0161589020303497 Peptide inhibition of acute lung injury in a novel two-hit rat model AC Sampson, BP Lassiter, M Gregory Rivera, PS Hair - Plos one, 2021 - journals.plos.orghttps://journals.plos.org/plosone/article?id=10.1371/journal.pone.0259133 Chemical approaches to modulating complement-mediated diseases A Iyer , W Xu, RC Reid , DP Fairlie - Journal of Medicinal Chemistry, 2017 - ACS Publicationshttps://pubs.acs.org/doi/abs/10.1021/acs.jmedchem.7b00882

• Marque: Biosynth